Anbio BiotechnologyNNNN +2.88%24 Altman Z2-Score is 370.31 as of Jul. 04, 2026, which is 1511% above its 10-year median of 22.98. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 844 Medical Devices & Instruments companies, Anbio Biotechnology ranks better than 99.76% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Anbio Biotechnology has a Altman Z2-Score of 370.31, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Anbio Biotechnology's Altman Z2-Score or its related term are showing as below:
NNNN'
s Altman Z2-Score Range Over the Past 10 Years
Min: 9.65 Med: 22.98 Max: 370.31
Current: 370.31
During the past 5 years, Anbio Biotechnology's highest Altman Z2-Score was 370.31. The lowest was 9.65. And the median was 22.98.
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
Anbio Biotechnology Altman Z2-Score Related Terms
Anbio Biotechnology Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNNN vs ANGO, OSUR, UTMD: Altman Z2-Score Comparison
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology Altman Z2-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
Anbio Biotechnology's Altman Z2-Score for today is calculated with this formula:
Z
=
6.56
*
X1
+
3.26
*
X2
+
6.72
*
X3
+
1.05
*
X4_2
=
6.56
*
0.9971
+
3.26
*
0.7796
+
6.72
*
0.2117
+
1.05
*
342.6705
=
370.31
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Anbio Biotechnology (NNNN) has a Altman Z2-Score of 370.31 as of Jul. 04, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Anbio Biotechnology and its competitors. This is 1511% above median its historical median of 22.98. Over the past decade, Anbio Biotechnology's Altman Z2-Score has ranged from 9.65 to 370.31. According to the industry distribution chart, Anbio Biotechnology ranks #2 out of 844 companies in the Medical Devices & Instruments industry, placing it in the top 0.2%.
Is Anbio Biotechnology's Altman Z2-Score too high?
Anbio Biotechnology's current Altman Z2-Score of 370.31 is 1511% above median its 10-year median of 22.98. Over the past 10 years, this metric has ranged from a low of 9.65 to a high of 370.31. The Medical Devices & Instruments industry median Altman Z2-Score is 3.48. Anbio Biotechnology's value of 370.31 is 10541.1% above this industry median. Based on the distribution chart, Anbio Biotechnology ranks #2 out of 844 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's Altman Z2-Score compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #2 out of 844 companies for Altman Z2-Score. This places Anbio Biotechnology in the top 0% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 3.48. Anbio Biotechnology's value of 370.31 is 10541.1% above this benchmark. Historically, Anbio Biotechnology's own Altman Z2-Score has ranged from 9.65 to 370.31 over the past decade. While the company's 10-year median is 22.98 vs. the industry median of 3.48, Anbio Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Devices & Instruments company?
The median Altman Z2-Score among Medical Devices & Instruments companies is 3.48, based on 844 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current Altman Z2-Score of 370.31 is 10541.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median Altman Z2-Score is 3.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current Altman Z2-Score is 370.31, which is 1511% above median its own 10-year median of 22.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current Altman Z2-Score of 370.31. The current Altman Z2-Score is 370.31, which is 1511% above median its 10-year median of 22.98 and 10541.1% above the Medical Devices & Instruments industry median of 3.48. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current Altman Z2-Score is 370.31 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
